<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786719</url>
  </required_header>
  <id_info>
    <org_study_id>H-38179 (SPRING)</org_study_id>
    <secondary_id>SPRING</secondary_id>
    <nct_id>NCT02786719</nct_id>
  </id_info>
  <brief_title>High-Risk Neuroblastoma Chemotherapy Without G-CSF</brief_title>
  <acronym>SPRING</acronym>
  <official_title>A Safety Pilot Study of High Risk Induction Chemotherapy for Neuroblastoma Without Prophylactic Administration of Myeloid Growth Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be asked to participate in this study because patients have been diagnosed with
      high-risk neuroblastoma, a common childhood cancer which has aggressive features. If left
      untreated, high-risk neuroblastoma is fatal. Children with high-risk neuroblastoma often
      respond to current available treatments, but there is a high risk that the cancer will
      return.

      This study will test the safety of giving standard induction treatment for high-risk
      neuroblastoma without one of the drugs commonly used to prevent side effects. Current
      treatment for high-risk neuroblastoma includes anti-cancer drugs (chemotherapy), surgery,
      radiation therapy and high-dose chemotherapy with hematopoietic stem cell rescue. Treatment
      takes about one year to complete and occurs in 3 phases: induction, consolidation, and
      maintenance. This study is limited to the induction phase of treatment.

      Induction therapy includes six chemotherapy drugs given in different combinations every 3
      weeks for a total of 6 courses. For the past decade, induction chemotherapy has been followed
      by a drug called granulocyte colony stimulating factor (G-CSF, filgrastim, peg-filgrastim,
      Neupogen, or Neulasta) to prevent side effects from the chemotherapy. G-CSF is routinely
      given to patients with high risk neuroblastoma after chemotherapy to stimulate white blood
      cell production and shorten the time period when the absolute neutrophil count (ANC), a type
      of white blood cell, is low after chemotherapy. G-CSF is known to shorten the period of low
      ANC by approximately 3 days. When the ANC is lowest, a patient is most at risk of getting a
      bacterial infection.

      Recent lab experiments in mice have shown that neuroblastoma tumor cells may respond to G-CSF
      by growing faster and metastasizing (spreading to other parts of the body). There have been
      no clinical trials comparing the survival of children with high risk neuroblastoma with or
      without G-CSF. This clinical trial is the first step towards giving induction chemotherapy
      with less G-CSF.

      The goal of this study is to determine if it is safe to give induction chemotherapy to
      children with neuroblastoma without giving G-CSF routinely.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy:

      CYCLE 1+2: Topotecan and cyclophosphamide

      Cycle 3+5: Cisplatin and Etoposide

      Cycle 4+6: Vincristine, Cyclophosphamide and Doxorubicin

      Stem cell collection: After the third cycle of chemotherapy, stem cells will be collected for
      possible stem cell transplantation at a later date using apheresis. In order to have enough
      stem cells present in the blood, the patient will need to receive daily G-CSF injections
      before this collection.

      Surgery: After the 5th cycle of chemotherapy, most patients will have surgery to remove as
      much remaining tumor as possible.

      Growth factor support: Growth factors to increase the number of white blood cells, G-CSF and
      GM-CSF(granulocyte-macrophage colony stimulating factor) will not be given routinely in this
      study. GM-CSF will be given for patients who have serious bacterial infections or delays in
      administering chemotherapy because of low neutrophil counts. All people enrolled on the study
      will receive GM-CSF prior to having surgical removal of the main tumor. All people enrolled
      on the study will also receive G-CSF prior to having patients stem cells collected.

      Optional survey: This research study includes an optional survey regarding quality of life
      while on the study. This survey will be filled out after cycles 1 and 4 of chemotherapy.

      Drug Shortages:

      In the event of a drug shortage of a medication that is not a G-CSF or GM-CSF product, the
      provider may use best clinical judgment regarding omission of the agent or substitution with
      a different agent. The medical and research records of study patients should reflect that the
      patient was informed of any delays and/or modifications in protocol therapy related to the
      shortage of the agent and the associated risks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">February 5, 2019</completion_date>
  <primary_completion_date type="Actual">February 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Infection</measure>
    <time_frame>through study completion, approximately 5 months</time_frame>
    <description>Incidence of infections in chemotherapy cycles NOT followed by hematopoietic growth factors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delay in Chemotherapy Administration Due to Prolonged Neutrophil Recovery</measure>
    <time_frame>through study completion, approximately 5 months</time_frame>
    <description>incidence of delay in chemotherapy administration due to prolonged neutrophil recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Response Rate Following Induction Chemotherapy Without Prophylactic Granulocyte Colony Stimulating Factor (G-CSF)</measure>
    <time_frame>through study completion, approximately 5 months</time_frame>
    <description>Response rate in the participants that completed all 6 cycles of induction chemotherapy on study. Response rate as categorize by International neuroblastoma response criteria.
Complete response (CR): No evidence of primary tumor; no evidence of metastases (chest, abdomen, liver, bone, bone marrow, nodes, etc.), and urine catecholamines homovanillic acid (HVA)/ vanillylmandelic acid (VMA) normal. MIBG scan must be negative to qualify for CR.
Very good partial response (VGPR): Greater than 90% reduction in primary tumor; no metastatic tumor (as above except bone); no new bone lesions, all pre-existing lesions improved, HVA/VMA normal
Partial Response (PR): 50-90% reduction of primary tumor; 50% or greater reduction in measurable sites of metastases; 0-1 bone marrow samples with tumor; number of positive bone sites decreased by 50%</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Neuroblastoma treatment without G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy only, including 6 cycles of chemotherapy, tumor resection, and stem cell collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>CYCLE 1+2 (given by intravenous catheter daily for 5 days)</description>
    <arm_group_label>Neuroblastoma treatment without G-CSF</arm_group_label>
    <other_name>hycamtin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>CYCLE 1+2 (given by intravenous catheter daily for 5 days)</description>
    <arm_group_label>Neuroblastoma treatment without G-CSF</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cycle 3+5 (given daily x 4 days)</description>
    <arm_group_label>Neuroblastoma treatment without G-CSF</arm_group_label>
    <other_name>CDDP</other_name>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Cycle 3+5 (given daily for 3 days)</description>
    <arm_group_label>Neuroblastoma treatment without G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Cycle 4+6 (given daily for 3 days)</description>
    <arm_group_label>Neuroblastoma treatment without G-CSF</arm_group_label>
    <other_name>Oncovin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cycle 4+6 (given daily for 2 days)</description>
    <arm_group_label>Neuroblastoma treatment without G-CSF</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Cycle 4+6 (given daily for 3 days)</description>
    <arm_group_label>Neuroblastoma treatment without G-CSF</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)</description>
    <arm_group_label>Neuroblastoma treatment without G-CSF</arm_group_label>
    <other_name>GM-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 12 months and less than 18 years old at diagnosis

          -  Newly diagnosed neuroblastoma or ganglioneuroblastoma as verified by histology and/or
             demonstration of tumor cells in bone marrow with elevated urinary catecholamine
             metabolites

          -  Must meet criteria for High Risk disease

               -  Patients with International Neuroblastoma Staging System (INSS) stage 4 disease
                  are eligible with the following: MYCN gene amplification (greater than four-fold
                  increase in MYCN signals as compared to reference signals), regardless of age or
                  additional biologic features, Age greater than 18 months ( greater than 547 days)
                  regardless of biologic features, Age 12 -18 months (365 - 547 days) with any of
                  the following unfavorable biologic features (unfavorable pathology and/or DNA
                  index = 1) or any biologic feature that is indeterminate/unsatisfactory/unknown

               -  Patients with INSS stage 3 disease are eligible with the following: MYCN
                  amplification, regardless of age or additional biologic features, Age greater
                  than 18 months ( greater than 547 days) with unfavorable pathology, regardless of
                  MYCN status

               -  Patients with INSS stage 2a/2b with MYCN amplification regardless of age or
                  additional biologic features

               -  Patients greater than or equal to 365 days initially diagnosed with INSS stage 1
                  or 2 who progressed to a stage 4 without interval chemotherapy

          -  Patients may have had no prior systemic therapy except: Localized emergency radiation
             to sites of life threatening or functioning disease, No more than 1 cycle of
             chemotherapy according to low or intermediate risk regimens prior to determination of
             MYCN amplification and histology, as long as the patient DID NOT receive any type of
             granulocyte colony stimulating factor (G-CSF) as part of that therapy.

          -  Patients must have adequate hematopoietic function defined as: Absolute neutrophil
             count (ANC) greater than or equal to 750/μL, Platelet count greater than or equal to
             75,000/μL, The above criteria do not have to be met if the patient has bone marrow
             involvement of tumor.

          -  Patients must have adequate liver function defined as: Direct bilirubin less than or
             equal to 1.5 mg/dL or total bilirubin ≤ 1.5 mg/dL, aspartate aminotrasnferase (AST)
             and alanine aminotransferase (ALT) less than or equal to10 x upper limit of normal for
             age

          -  Patients must have adequate renal function as defined as: Creatinine clearance (CrCl)
             or radioisotope glomerular filtration rate (GFR) greater than or equal to 70
             mL/min/.73 m2 OR A serum creatinine based on age/gender.

          -  Patients must have adequate cardiac function as defined as: Shortening fraction of
             greater than or equal to 27 % by echocardiogram, or Ejection fraction of greater than
             or equal to 50 % by radionuclide angiogram

        Exclusion Criteria:

          -  Patients who do not meet inclusion criteria

          -  Patients who are pregnant or lactating

          -  Patients who have received G-CSF since the time of diagnosis of the current disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Whittle, MD, BA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 23, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <results_first_submitted>February 4, 2020</results_first_submitted>
  <results_first_submitted_qc>March 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2020</results_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Sarah Whittle</investigator_full_name>
    <investigator_title>Instructor</investigator_title>
  </responsible_party>
  <keyword>Sargramostim</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Topotecan</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Dexrazoxane</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Etoposide</keyword>
  <keyword>Filgrastim</keyword>
  <keyword>Vincristine</keyword>
  <keyword>Mesna</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT02786719/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Risk Neuroblastoma Patients</title>
          <description>This was a single arm study- all participants enrolled in single arm which provided 6 cycles of chemotherapy without prophylactic G-CSF for 4 cycles (1,2,4 and 6), and with G-CSF for stem cell collection after cycle 3, and GM-CSF administration after cycle 5 in preparation for surgical resection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>all participants evaluable for infection endpoint</population>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>Single arm study- all participants enrolled in single arm</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" lower_limit="1.1" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Neuroblastoma Risk Group Stage</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>L2 (localized with image defined risk factors)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M (metastatic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MYCN gene amplification</title>
          <description>Amplification of MYCN gene, a poor prognostic factor in neuroblastoma</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marrow involvement</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Infection</title>
        <description>Incidence of infections in chemotherapy cycles NOT followed by hematopoietic growth factors</description>
        <time_frame>through study completion, approximately 5 months</time_frame>
        <population>Includes all patients evaluable for endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>High Risk Neuroblastoma Patients</title>
            <description>Single arm study- all participants enrolled in single arm</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Infection</title>
          <description>Incidence of infections in chemotherapy cycles NOT followed by hematopoietic growth factors</description>
          <population>Includes all patients evaluable for endpoint</population>
          <units>infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delay in Chemotherapy Administration Due to Prolonged Neutrophil Recovery</title>
        <description>incidence of delay in chemotherapy administration due to prolonged neutrophil recovery</description>
        <time_frame>through study completion, approximately 5 months</time_frame>
        <population>58 cycles of chemotherapy administered to 12 participants</population>
        <group_list>
          <group group_id="O1">
            <title>High Risk Neuroblastoma Patients</title>
            <description>Single arm study- all participants enrolled in single arm</description>
          </group>
        </group_list>
        <measure>
          <title>Delay in Chemotherapy Administration Due to Prolonged Neutrophil Recovery</title>
          <description>incidence of delay in chemotherapy administration due to prolonged neutrophil recovery</description>
          <population>58 cycles of chemotherapy administered to 12 participants</population>
          <units>chemotherapy cycles</units>
          <param>Number</param>
          <units_analyzed>Chemotherapy cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Chemotherapy cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Response Rate Following Induction Chemotherapy Without Prophylactic Granulocyte Colony Stimulating Factor (G-CSF)</title>
        <description>Response rate in the participants that completed all 6 cycles of induction chemotherapy on study. Response rate as categorize by International neuroblastoma response criteria.
Complete response (CR): No evidence of primary tumor; no evidence of metastases (chest, abdomen, liver, bone, bone marrow, nodes, etc.), and urine catecholamines homovanillic acid (HVA)/ vanillylmandelic acid (VMA) normal. MIBG scan must be negative to qualify for CR.
Very good partial response (VGPR): Greater than 90% reduction in primary tumor; no metastatic tumor (as above except bone); no new bone lesions, all pre-existing lesions improved, HVA/VMA normal
Partial Response (PR): 50-90% reduction of primary tumor; 50% or greater reduction in measurable sites of metastases; 0-1 bone marrow samples with tumor; number of positive bone sites decreased by 50%</description>
        <time_frame>through study completion, approximately 5 months</time_frame>
        <population>Completed all 6 cycles of induction chemotherapy on study</population>
        <group_list>
          <group group_id="O1">
            <title>High Risk Neuroblastoma Patients</title>
            <description>Single arm study- all participants enrolled in single arm</description>
          </group>
        </group_list>
        <measure>
          <title>the Response Rate Following Induction Chemotherapy Without Prophylactic Granulocyte Colony Stimulating Factor (G-CSF)</title>
          <description>Response rate in the participants that completed all 6 cycles of induction chemotherapy on study. Response rate as categorize by International neuroblastoma response criteria.
Complete response (CR): No evidence of primary tumor; no evidence of metastases (chest, abdomen, liver, bone, bone marrow, nodes, etc.), and urine catecholamines homovanillic acid (HVA)/ vanillylmandelic acid (VMA) normal. MIBG scan must be negative to qualify for CR.
Very good partial response (VGPR): Greater than 90% reduction in primary tumor; no metastatic tumor (as above except bone); no new bone lesions, all pre-existing lesions improved, HVA/VMA normal
Partial Response (PR): 50-90% reduction of primary tumor; 50% or greater reduction in measurable sites of metastases; 0-1 bone marrow samples with tumor; number of positive bone sites decreased by 50%</description>
          <population>Completed all 6 cycles of induction chemotherapy on study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Partial response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very good partial response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reporting period for each patient was from enrolling on trial until ANC recovery &gt;750 from final cycle of chemotherapy administered while patient on study (max of 6 cycles).</time_frame>
      <desc>A systematic assessment was performed using regular laboratory assessment as well as regular investigator assessment of clinical records for AEs.
All-Cause Mortality was assessed for all 13 participants who signed the informed consent. Serious and Other (Not Including Serious) Adverse Events were only assessed for the 12 participants who received treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>High Risk Neuroblastoma Patients</title>
          <description>Single arm study- all participants enrolled in single arm</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusoidal obstruction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin/soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Anemia</description>
                <counts group_id="E1" events="73" subjects_affected="12" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Neutrophil count decreased</description>
                <counts group_id="E1" events="100" subjects_affected="12" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Platelet count decreased</description>
                <counts group_id="E1" events="93" subjects_affected="12" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>WBC decreased</sub_title>
                <description>White blood cell decreased</description>
                <counts group_id="E1" events="119" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>Weight loss</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <description>Alanine aminotransferase increased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Alk phos increased</sub_title>
                <description>Alkaline phosphatase increased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <description>Aspartate aminotransferase increased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Pain in extremity</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>Pleural effusion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Rash</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was designed to pilot safely decreasing exposure to G-CSF. To formally test the non-inferiority of not giving G-CSF a much larger sample size would be needed. This study does not conclude that G-CSF prevents infections.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sarah Whittle, MD MS</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>8328241471</phone>
      <email>whittle@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

